Trial Status: Complete
Recruitment closed January 2016
This is a multi-centre randomised, double blind, placebo-controlled, parallel group trial of the effectiveness of the nocturnal use of a Temperature Controlled Laminar Airflow (TLA) Device (Airsonett®) in adults with poorly-controlled, severe allergic asthma
The trial is assessing whether a new treatment device might help to reduce the frequency of severe asthma attacks in patients with allergic asthma.
Asthma affects over 5 million people in the UK. Half a million of these have a severe form of the condition. Potentially life threatening attacks, known as exacerbations, are a frequent occurrence. Current treatment options to reduce the frequency of these exacerbations are limited.
The LASER trial will evaluate the effectiveness of a new treatment – Temperature Controlled Laminar Airflow (TLA.) TLA is delivered by an Airsonett® machine. The machine is used overnight in the patient’s home at the bedside. The machine filters allergy particles from the air overnight, allowing patients to sleep and ‘rest’ their lungs.
The primary results publication can be found here.
The protocol publication can be found here.